March 2, 2024

Oncology Molecular Diagnostic Market Size At Around US$ 7.71 Bn In 2033

The oncology molecular diagnostic market would grow at a CAGR of 12.20% over the predicted time frame. The market is expected to increase in value from US$ 2.45 billion in 2023 to US$ 7.71 billion by 2033.

Oncology Molecular Diagnostic Market Size 2024 To 2033

Key Takeaways

  • North America contributed more than 41% of the market share in 2023.
  • Asia-Pacific is estimated to expand the fastest CAGR between 2024 and 2033.
  • By type, the breast cancer segment generated over 22% of the market share in 2023.
  • By type, the liver cancer segment is anticipated to grow at a remarkable CAGR of 13.9% between 2024 and 2033.
  • By technology, the polymerase chain reaction (PCR) segment generated over 32% of the market share in 2023.
  • By technology, the sequencing segment is expected to expand at the fastest CAGR over the projected period.
  • By product, the reagents segment generated over 59% of market share in 2023.
  • By product, the instruments segment is expected to expand at the fastest CAGR over the projected period.

The on oncology molecular diagnostic Market, which provides a business strategy, research & development activities, concise outline of the market valuation, valuable insights pertaining to market share, size, supply chain analysis, competitive landscape and regional proliferation of this industry.

Download Free Sample@ https://www.precedenceresearch.com/sample/3677

A recent report provides crucial insights along with application based and forecast information in the Global Oncology molecular diagnostic Market. The report provides a comprehensive analysis of key factors that are expected to drive the growth of this market. This study also provides a detailed overview of the opportunities along with the current trends observed in the Oncology molecular diagnostic market.

A quantitative analysis of the industry is compiled for a period of 10 years in order to assist players to grow in the market. Insights on specific revenue figures generated are also given in the report, along with projected revenue at the end of the forecast period.

Oncology Molecular Diagnostic Market  Scope

Report CoverageDetails
Growth Rate from 2024 to 2033CAGR of 12.20%
Global Market Size in 2023USD 2.45 Billion
Global Market Size by 2033USD 7.71 Billion
U.S. Market Size in 2023USD 0.70 Billion
U.S. Market Size by 2033USD 2.25 Billion
Base Year2023
Forecast Period2024 to 2033
Segments CoveredBy Type, By Technology and By Product
Regions CoveredNorth America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Read Also: Emergency Department Information System Market Size, Trend Report 2032

Companies and Manufacturers Covered

The study covers key players operating in the market along with prime schemes and strategies implemented by each player to hold high positions in the industry. Such a tough vendor landscape provides a competitive outlook of the industry, consequently existing as a key insight. These insights were thoroughly analysed and prime business strategies and products that offer high revenue generation capacities were identified. Key players of the global Oncology molecular diagnostic market are included as given below:

Oncology Molecular Diagnostic Market Companies

  • Roche Diagnostics
  • Abbott Laboratories
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • Qiagen N.V.
  • Bio-Rad Laboratories, Inc.
  • Genomic Health, Inc.
  • Myriad Genetics, Inc.
  • Agilent Technologies, Inc.
  • Siemens Healthineers
  • Danaher Corporation (Cepheid)
  • Sysmex Corporation
  • Hologic, Inc.
  • Guardant Health, Inc.
  • Foundation Medicine, Inc.

Segments Covered in the Report:

By Type

  • Breast Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Cervical Cancer
  • Liver Cancer
  • Lung Cancer
  • Blood Cancer
  • Kidney Cancer
  • Other Cancer

By Technology

  • PCR
  • In Situ Hybridization
  • INAAT
  • Chips and Microarrays
  • Mass Spectrometry
  • Sequencing
  • TMA
  • Others

By Product

  • Instruments
  • Reagents
  • Others

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

Report Objectives

  • To define, describe, and forecast the global oncology molecular diagnostic market based on product, and region
  • To provide detailed information regarding the major factors influencing the growth of the market (drivers, opportunities, and industry-specific challenges)
  • To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the total market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of market segments with respect to four main regions—North America, Europe, Asia Pacific and the Rest of the World (RoW)2
  • To strategically profile key players and comprehensively analyze their product portfolios, market shares, and core competencies3
  • To track and analyze competitive developments such as acquisitions, expansions, new product launches, and partnerships in the oncology molecular diagnostic market

Table of Content

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Oncology Molecular Diagnostic Market 

5.1. COVID-19 Landscape: Oncology Molecular Diagnostic Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Oncology Molecular Diagnostic Market, By Type

8.1. Oncology Molecular Diagnostic Market Revenue and Volume, by Type, 2024-2033

8.1.1 Breast Cancer

8.1.1.1. Market Revenue and Volume Forecast (2021-2033)

8.1.2. Prostate Cancer

8.1.2.1. Market Revenue and Volume Forecast (2021-2033)

8.1.3. Colorectal Cancer

8.1.3.1. Market Revenue and Volume Forecast (2021-2033)

8.1.4. Cervical Cancer

8.1.4.1. Market Revenue and Volume Forecast (2021-2033)

8.1.5. Liver Cancer

8.1.5.1. Market Revenue and Volume Forecast (2021-2033)

8.1.6. Lung Cancer

8.1.6.1. Market Revenue and Volume Forecast (2021-2033)

8.1.7. Lung Cancer

8.1.7.1. Market Revenue and Volume Forecast (2021-2033)

8.1.8. Blood Cancer

8.1.8.1. Market Revenue and Volume Forecast (2021-2033)

8.1.9. Kidney Cancer

8.1.9.1. Market Revenue and Volume Forecast (2021-2033)

8.1.10. Other Cancer

8.1.10.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 9. Global Oncology Molecular Diagnostic Market, By February

9.1. Oncology Molecular Diagnostic Market Revenue and Volume, by February, 2024-2033

9.1.1. Cathode

9.1.1.1. Market Revenue and Volume Forecast (2021-2033)

9.1.2. Anode

9.1.2.1. Market Revenue and Volume Forecast (2021-2033)

9.1.3. Electrolyte

9.1.3.1. Market Revenue and Volume Forecast (2021-2033)

9.1.4. Separator

9.1.4.1. Market Revenue and Volume Forecast (2021-2033)

9.1.5. Others

9.1.5.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 10. Global Oncology Molecular Diagnostic Market, By March 

10.1. Oncology Molecular Diagnostic Market Revenue and Volume, by March, 2024-2033

10.1.1. Consumer

10.1.1.1. Market Revenue and Volume Forecast (2021-2033)

10.1.2. Automotive

10.1.2.1. Market Revenue and Volume Forecast (2021-2033)

10.1.3. Industrial

10.1.3.1. Market Revenue and Volume Forecast (2021-2033)

10.1.4. Cheese

10.1.4.1. Market Revenue and Volume Forecast (2021-2033)

10.1.5. Others

10.1.5.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 11. Global Oncology Molecular Diagnostic Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.1.2. Market Revenue and Volume Forecast, by February (2021-2033)

11.1.3. Market Revenue and Volume Forecast, by March (2021-2033)

11.1.4. U.S.

11.1.4.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.1.4.2. Market Revenue and Volume Forecast, by February (2021-2033)

11.1.4.3. Market Revenue and Volume Forecast, by March (2021-2033)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.1.5.2. Market Revenue and Volume Forecast, by February (2021-2033)

11.1.5.3. Market Revenue and Volume Forecast, by March (2021-2033)

11.2. Europe

11.2.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.2.2. Market Revenue and Volume Forecast, by February (2021-2033)

11.2.3. Market Revenue and Volume Forecast, by March (2021-2033)

11.2.4. UK

11.2.4.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.2.4.2. Market Revenue and Volume Forecast, by February (2021-2033)

11.2.4.3. Market Revenue and Volume Forecast, by March (2021-2033)

11.2.5. Germany

11.2.5.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.2.5.2. Market Revenue and Volume Forecast, by February (2021-2033)

11.2.5.3. Market Revenue and Volume Forecast, by March (2021-2033)

11.2.6. France

11.2.6.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.2.6.2. Market Revenue and Volume Forecast, by February (2021-2033)

11.2.6.3. Market Revenue and Volume Forecast, by March (2021-2033)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.2.7.2. Market Revenue and Volume Forecast, by February (2021-2033)

11.2.7.3. Market Revenue and Volume Forecast, by March (2021-2033)

11.3. APAC

11.3.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.3.2. Market Revenue and Volume Forecast, by February (2021-2033)

11.3.3. Market Revenue and Volume Forecast, by March (2021-2033)

11.3.4. India

11.3.4.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.3.4.2. Market Revenue and Volume Forecast, by February (2021-2033)

11.3.4.3. Market Revenue and Volume Forecast, by March (2021-2033)

11.3.5. China

11.3.5.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.3.5.2. Market Revenue and Volume Forecast, by February (2021-2033)

11.3.5.3. Market Revenue and Volume Forecast, by March (2021-2033)

11.3.6. Japan

11.3.6.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.3.6.2. Market Revenue and Volume Forecast, by February (2021-2033)

11.3.6.3. Market Revenue and Volume Forecast, by March (2021-2033)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.3.7.2. Market Revenue and Volume Forecast, by February (2021-2033)

11.3.7.3. Market Revenue and Volume Forecast, by March (2021-2033)

11.4. MEA

11.4.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.4.2. Market Revenue and Volume Forecast, by February (2021-2033)

11.4.3. Market Revenue and Volume Forecast, by March (2021-2033)

11.4.4. GCC

11.4.4.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.4.4.2. Market Revenue and Volume Forecast, by February (2021-2033)

11.4.4.3. Market Revenue and Volume Forecast, by March (2021-2033)

11.4.5. North Africa

11.4.5.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.4.5.2. Market Revenue and Volume Forecast, by February (2021-2033)

11.4.5.3. Market Revenue and Volume Forecast, by March (2021-2033)

11.4.6. South Africa

11.4.6.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.4.6.2. Market Revenue and Volume Forecast, by February (2021-2033)

11.4.6.3. Market Revenue and Volume Forecast, by March (2021-2033)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.4.7.2. Market Revenue and Volume Forecast, by February (2021-2033)

11.4.7.3. Market Revenue and Volume Forecast, by March (2021-2033)

11.5. Latin America

11.5.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.5.2. Market Revenue and Volume Forecast, by February (2021-2033)

11.5.3. Market Revenue and Volume Forecast, by March (2021-2033)

11.5.4. Brazil

11.5.4.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.5.4.2. Market Revenue and Volume Forecast, by February (2021-2033)

11.5.4.3. Market Revenue and Volume Forecast, by March (2021-2033)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.5.5.2. Market Revenue and Volume Forecast, by February (2021-2033)

11.5.5.3. Market Revenue and Volume Forecast, by March (2021-2033)

Chapter 12. Company Profiles

12.1. Roche Diagnostics

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Abbott Laboratories

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Thermo Fisher Scientific Inc.

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Illumina, Inc.

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Qiagen N.V.

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Bio-Rad Laboratories, Inc.

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Genomic Health, Inc.

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Myriad Genetics, Inc.

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Agilent Technologies, Inc.

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Siemens Healthineers

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Contact Us:

Precedence Research

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call: +1 774 402 6168

Email: sales@precedenceresearch.com

Website: https://www.precedenceresearch.com

 Blog: https://www.pharma-geek.com